Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Novel, Potent, and Selective GABAC Antagonists Inhibit Myopia Development and Facilitate Learning and Memory

Mary Chebib, Tina Hinton, Katrina L. Schmid, Darren Brinkworth, Haohua Qian, Susana Matos, Hye-Lim Kim, Heba Abdel-Halim, Rohan J. Kumar, Graham A. R. Johnston and Jane R. Hanrahan
Journal of Pharmacology and Experimental Therapeutics February 2009, 328 (2) 448-457; DOI: https://doi.org/10.1124/jpet.108.146464
Mary Chebib
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina Hinton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrina L. Schmid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darren Brinkworth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haohua Qian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susana Matos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hye-Lim Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heba Abdel-Halim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rohan J. Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham A. R. Johnston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane R. Hanrahan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This study reports pharmacological and physiological effects of cis- and trans-(3-aminocyclopentanyl)butylphosphinic acid (cis- and trans-3-ACPBPA). These compounds are conformationally restricted analogs of the orally active GABAB/C receptor antagonist (3-aminopropyl)-n-butylphosphinic acid (CGP36742 or SGS742). cis-[IC50(ρ1) = 5.06 μM and IC50(ρ2) = 11.08 μM; n = 4] and trans-3-ACPMPA [IC50(ρ1) = 72.58 μM and IC50(ρ2) = 189.7 μM; n = 4] seem competitive at GABAC receptors expressed in Xenopus laevis oocytes, having no effect as agonists (1 mM) but exerting weak antagonist (1 mM) effects on human GABAA and GABAB receptors. cis-3-ACPBPA was more potent and selective than the trans-compound, being more than 100 times more potent at GABAC than GABAA or GABAB receptors. cis-3-ACPBPA was further evaluated on dissociated rat retinal bipolar cells and dose-dependently inhibited the native GABAC receptor (IC50 = 47 ± 4.5 μM; n = 6). When applied to the eye as intravitreal injections, cis- and trans-3-ACPBPA prevented experimental myopia development and inhibited the associated vitreous chamber elongation, in a dose-dependent manner in the chick model. Doses only 10 times greater than required to inhibit recombinant GABAC receptors caused the antimyopia effects. Using intraperitoneal administration, cis- (30 mg/kg) and trans-3-ACPBPA (100 mg/kg) enhanced learning and memory in male Wistar rats; compared with vehicle there was a significant reduction in time for rats to find the platform in the Morris water maze task (p < 0.05; n = 10). As the physiological effects of cis- and trans-3-ACPBPA are similar to those reported for CGP36742, the memory and refractive effects of CGP36742 may be due in part to its GABAC activity.

Footnotes

  • This work was supported in part by the National Institutes of Health [Grant EY12028], Circadian Technologies Pty. Ltd., and the Institute of Health and Biomedical Innovation.

  • This article contains data presented in part in Schmid KL, Brinkworth D, Wallace KM, Payer R, Fritsch C, and Lambrou GN (2004) The effects of GABA-B and GABA-C antagonists on myopia development in chick, in Proceedings of the 10th International Conference on Myopia; 2004 July 19–22; Cambridge, UK; and Schmid KL, Brinkworth DR, Chebib M, Hanrahan JR, and Johnston GAR (2005) A theoretical model for GABAc antagonists inhibiting myopia via the ON/OFF retinal pathway, in Proceedings of the Joint Meeting of Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and Australasian Pharmaceutical Science Association; 2005 December; Melbourne, Australia.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.108.146464.

  • ABBREVIATIONS: TPMPA, (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid; 3-APMPA, (3-aminopropyl)-methylphosphinic acid; cis- and trans-3-ACPMPA, cis- and trans-(3-aminocyclopentanyl)methylphosphinic acid; cis- and trans-3-ACPBPA, cis- and trans-(3-aminocyclopentanyl)butylphosphinic acid; CGP36742 or SGS742, (3-aminopropyl)-n-butylphosphinic acid; GIRK, G protein-coupled inwardly rectifying potassium channel; D, diopter.

    • Received September 22, 2008.
    • Accepted November 3, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 384 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 384, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel, Potent, and Selective GABAC Antagonists Inhibit Myopia Development and Facilitate Learning and Memory
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Novel, Potent, and Selective GABAC Antagonists Inhibit Myopia Development and Facilitate Learning and Memory

Mary Chebib, Tina Hinton, Katrina L. Schmid, Darren Brinkworth, Haohua Qian, Susana Matos, Hye-Lim Kim, Heba Abdel-Halim, Rohan J. Kumar, Graham A. R. Johnston and Jane R. Hanrahan
Journal of Pharmacology and Experimental Therapeutics February 1, 2009, 328 (2) 448-457; DOI: https://doi.org/10.1124/jpet.108.146464

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Novel, Potent, and Selective GABAC Antagonists Inhibit Myopia Development and Facilitate Learning and Memory

Mary Chebib, Tina Hinton, Katrina L. Schmid, Darren Brinkworth, Haohua Qian, Susana Matos, Hye-Lim Kim, Heba Abdel-Halim, Rohan J. Kumar, Graham A. R. Johnston and Jane R. Hanrahan
Journal of Pharmacology and Experimental Therapeutics February 1, 2009, 328 (2) 448-457; DOI: https://doi.org/10.1124/jpet.108.146464
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Substituted tryptamine activity at 5-HT receptors & SERT
  • In Vivo SRI-32743 Attenuates Tat Effects on Extracellular DA
  • Kv7 Opener Attenuates Seizures and Cognitive Deficit
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics